Meridian Bioscience CEO John Kraeutler: How We Turned Around A Deficient Quality System
This article was originally published in The Silver Sheet
Executive Summary
Meridian Bioscience’s quality system and company culture needed to change after the firm ran into regulatory trouble between 1999 and 2001, according to CEO John Kraeutler. “What I learned during those two years is, if you tell the FDA you’re going to do something, you really ought to do it,” he said. Meridian feared it was on the precipice of a consent decree with FDA and knew it had to act quickly. As a part of its culture change, the firm began urging employees to communicate important information to top management.
You may also be interested in...
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.
FDA Slaps High Risk Class I Label On Recall Of COVID-19 Diagnostics Made In Uncontrolled Plant
More than 160,000 of the tests were recalled, including 104,900 COVID Test Kits Nonsterile and 61,500 Clean Catch Urine Kits.